0 likes | 15 Views
The global metabolomics market is anticipated to grow with a CAGR of 13% over the forecast period, i.e., 2023-2033. The market is segmented by indication into cancer, cardiovascular disorders, and neurological disorders, out of which, the cancer segment is projected to display the largest revenue of ~USD 580 Billion by the end of 2033. Moreover, in the year 2022, the segment generated a revenue of ~USD 2 Billion.
E N D